文献速递免疫规划卫生政策与健康促进

英格兰老年人肺炎球菌免疫策略的影响与成本效果

The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
PubMed 文献 · Vaccine · 2024-05-18

本研究构建静态马尔可夫模型,比较英格兰65岁或75岁老年人接种PPV23、PCV15和PCV20预防肺炎球菌疾病的影响与成本效果。在基础疫苗有效性假设下,接种后30年内PCV20避免的IPD和CAP病例数多于PCV15或PPV23。按2023年5月列出的价格,PPV23和PCV20在每QALY 20,000英镑的ICER阈值下均具有成本效果。

要点

  • 接种后30年内,PCV20避免的IPD和CAP病例数多于PCV15或PPV23。
  • 按2023年5月列表价格,PPV23和PCV20在20,000英镑/QALY阈值下均具有成本效果。
  • 若接种年龄为65岁,PCV20额外成本需低于44英镑(20,000英镑/QALY)或91英镑(30,000英镑/QALY)才与PPV23成本效果相同。

核心结论

  • PPV23和PCV20均可能具有成本效果;在PCV20疫苗有效性更高且免疫力衰减更慢的输入假设下,PCV20可能比现行PPV23在英格兰老年人中避免更多肺炎球菌疾病病例。

研究设计与样本

  • 研究构建静态马尔可夫模型评估肺炎球菌免疫接种,纳入不同的疫苗有效性和免疫力衰减假设,预测接种后三十年避免的IPD/CAP病例数。
  • 研究使用经济模型和概率敏感性分析,按当前疫苗列表价格以及中位阈值20,000英镑/QALY和90%模拟低于30,000英镑/QALY的不确定性阈值评估不同免疫策略的成本效果。

主要发现

  • 在基础疫苗有效性假设下,接种后三十年内PCV20避免的IPD病例数为353例(接种年龄65岁)和360例(接种年龄75岁),PCV15为145例和159例,PPV23为150例和174例。
  • 在基础疫苗有效性假设下,接种后三十年内PCV20避免的CAP病例数为581例(接种年龄65岁)和673例(接种年龄75岁),PCV15为259例和485例,PPV23为212例和235例。

关键数值与推荐

  • 按2023年5月PCV20和PPV23疫苗的列表价格,在每QALY 20,000英镑的ICER阈值下,两种疫苗对65岁或75岁人群接种均具有成本效果。
  • 若接种年龄为65岁,在ICER阈值20,000英镑/QALY(30,000英镑/QALY)下,PCV20的额外成本应低于44英镑(91英镑)才能达到与PPV23相同的成本效果。
  • 若接种年龄提高到75岁,在ICER阈值20,000英镑/QALY(30,000英镑/QALY)下,PCV20的额外成本应低于54英镑(103英镑)才能达到与PPV23相同的成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pneumococcal disease, presenting as invasive pneumococcal disease (IPD) or community-acquired pneumonia (CAP) is an important cause of illness and hospitalisation in the elderly. To reduce pneumococcal burden, since 2003, 65-year-olds in England have been offered a 23-valent pneumococcal polysaccharide vaccine (PPV23). This study compares the impact and cost-effectiveness (CE) of vaccination with the existing PPV23 vaccine to the new 15-and 20-valent pneumococcal conjugate vaccines (PCV15 and PCV20), targeting adults aged 65 or 75 years old. We developed a static Markov model for immunisation against pneumococcal disease, capturing different vaccine effectiveness and immunity waning assumptions, projecting the number of IPD/CAP cases averted over the thirty years following vaccination. Using an economic model and probabilistic sensitivity analysis we evaluated the CE of the different immunisation strategies at current vaccine list prices and the willingness-to-pay at a median threshold of £20,000/QALY and an uncertainty threshold of 90% of simulations below £30,000/QALY. PCV20 averted more IPD and CAP cases than PCV15 or PPV23 over the thirty years following vaccination: 353(360), 145(159) and 150(174) IPD and 581(673), 259(485) and 212(235) CAP cases at a vaccination age of 65(75) under base vaccine effectiveness assumptions. At the listed prices of PCV20 and PPV23 vaccines as of May 2023, both vaccines were cost-effective when vaccinating 65- or 75-year-olds with an ICER threshold of £20,000 per QALY. To achieve the same cost-effectiveness as PPV23, the additional cost of PCV20 should be less than £44(£91) at an ICER threshold of £20,000/QALY (£30,000/QALY) if vaccination age is 65 (or £54(£103) if vaccination age is increased to 75). We showed that both PPV23 and PCV20 were likely to be cost-effective. PCV20 was likely to avert more cases of pneumococcal disease in elderly adults in England than the current PPV23 vaccine, given input assumptions of a higher vaccine effectiveness and slower waning for PCV20.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Danelian G, Burton L, Bayley T, et al. The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England. Vaccine. 2024. PMID: 38763851. doi:10.1016/j.vaccine.2024.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。